Hepatitis B DNA vaccine - ChronTech Pharma

Drug Profile

Hepatitis B DNA vaccine - ChronTech Pharma

Alternative Names: ChronVac-B

Latest Information Update: 15 Nov 2014

Price : $50

At a glance

  • Originator Inovio Biomedical Corporation; Tripep
  • Developer ChronTech Pharma; Inovio Pharmaceuticals
  • Class DNA vaccines; Hepatitis B vaccines
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 01 Sep 2014 Hepatitis B vaccine technology repurchased from Avac Pharma
  • 23 Aug 2013 Hepatitis B DNA vaccine technology sold to Avac Pharma
  • 12 Nov 2012 Immunogenicity data from a preclinical study in Hepatitis B released by Inovio Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top